GENinCode (LON:GENI) Sets New 12-Month Low – Here’s Why

GENinCode Plc (LON:GENI)’s share price hit a new 52-week low during trading on Wednesday. The company traded as low as GBX 0.61 and last traded at GBX 0.65, with a volume of 6513982 shares. The stock had previously closed at GBX 0.68.

GENinCode Stock Performance

The company has a debt-to-equity ratio of 4.75, a quick ratio of 15.88 and a current ratio of 2.22. The stock has a market cap of £4.89 million, a P/E ratio of -0.51 and a beta of 0.59. The firm’s 50 day moving average is GBX 0.87 and its 200 day moving average is GBX 0.97.

GENinCode (LON:GENI) last issued its quarterly earnings results on Tuesday, September 29th. The company reported GBX (0.38) earnings per share for the quarter. GENinCode had a negative return on equity of 481.34% and a negative net margin of 202.42%. Analysts anticipate that GENinCode Plc will post -7.1299999 EPS for the current year.

GENinCode Company Profile

GENinCode Plc is a UK based company specialising in genetic risk assessment of cardiovascular disease. Cardiovascular disease is the leading cause of death and disability worldwide.

GENinCode operates business units in the UK, in the United States through GENinCode U.S. Inc and in Europe through GENinCode S.L.U.

GENinCode predictive technology provides patients and physicians with globally leading preventative care and treatment strategies. GENinCode CE marked invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict disease onset.